CSG’s Q1 Earnings Surge 83% but the Stock Stays Stuck as KNDS Talks Cloud the Outlook

Czechoslovak Group reports 83% profit jump but shares near lows as it targets a stake in KNDS armour alliance and fortifies supply chain with Alzchem investment.

Tightening its grip on the European defence supply chain, Czechoslovak Group is pursuing a stake in the continent’s most prominent armour vehicles alliance. The move comes just as the company’s shares hit fresh lows, highlighting a widening gulf between operational strength and market sentiment.

CSG booked a 13.8% revenue rise in the first quarter to €1.54bn, while net profit surged 83% to €299mn. The Defence Systems division, its largest unit, powered the advance with a 26% jump in turnover to €1.25bn. The order backlog swelled 15% since year-end to roughly €17bn, underpinned by long?term ammunition contracts and sustained demand from European and North American customers.

Yet the stock continues to slide. Listed on Euronext Amsterdam in January 2026 at €25 a share, the equity now trades at €15.78 — just pennies above its recent trough of €15.73 and a long way from its record of €33.81. Wednesday’s session brought a further 1.82% decline, dragging the weekly loss to 11.34%. With an annualised 30?day volatility reading of 80.38%, the market clearly remains jittery.

The discord between the numbers and the price suggests investors are less concerned about demand than about the cost of expansion. CSG has signalled its intention to take a meaningful interest in KNDS, the holding company behind Germany’s Krauss?Maffei Wegmann and France’s Nexter, which together dominate the battle?tank and artillery business. While no details on the size or valuation of the proposed stake have been confirmed, the move would propel CSG from munitions and components into complete weapon platforms — a strategic leap that carries both industrial potential and political sensitivity.

At the same time, CSG is fortifying its supply?chain position. On 2 June it disclosed a total holding of 20.1% in Alzchem, the German speciality chemical group that produces precursor materials for propellant charges. The stake includes direct voting rights via Staluna Trade and financial instruments. The logic is clear: Alzchem secures raw?material access for the ammunition side, while KNDS would open the door to armoured vehicles and artillery systems.

Analysts remain broadly upbeat, despite the share?price headwind. The consensus on CSG stands at a “Strong Buy”, backed by ten analysts, with a mean price target of €32.05 — implying theoretical upside of more than 100% from current levels. Berenberg, however, trimmed its estimates and lowered its own target, citing mixed performance across segments in the opening quarter.

Technically the stock is stretched. It trades about 21% below its 50?day moving average and only 2.2% above the recent low. That leaves CSG vulnerable to fresh sector?wide catalysts. One such event is already under way: HEMUS 2026, the international defence fair in Plovdiv, opened on Wednesday with Bulgarian President Iliana Iotova in attendance. The show brings together 216 companies from 28 countries, including 18 Czech exhibitors, and features robotics, artificial intelligence and drone technology across more than 5,000 square metres. With 16 international delegations expected, the fair could generate new partnership announcements or order flow.

CSG will next update the market on 6 August 2026 with its half?year results. The key question for investors is whether the group can confirm its annual guidance and show enough balance?sheet headroom to pursue both the KNDS stake and further vertical integration without straining financial discipline. For now, the profits are booming — but the market is waiting for proof that growth doesn’t come at too high a price.